Lyell Immunopharma, Inc. — Director's Dealing 2025

Aug 14, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-08-11

Reporting Person: Lee Gary K. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-11	Common Stock	S	131	$10.526	Disposed	9093	Direct
2025-08-12	Common Stock	S	136	$10.338	Disposed	8957	Direct

Footnotes

F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

F4: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.

F5: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F6: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.